Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Is It Too Late to Buy Novo Nordisk After the Drop?
08:00am, Friday, 14'th Nov 2025
Novo Nordisk (NVO 2.27%) is in the spotlight after cutting guidance again, but analysts remain optimistic. With Ozempic and Wegovy driving strong sales and a 52% upside potential, this could be one of
Why Is Everyone Talking About Novo Nordisk Stock?
06:15am, Friday, 14'th Nov 2025
Novo Nordisk's latest quarterly update disappointed investors -- again. But the company has a lot going on behind the scenes that affects its outlook.
Novo Nordisk's leadership strategy tested as shareholders signal frustration ahead of vote on board revamp
03:48am, Friday, 14'th Nov 2025
Novo Nordisk last month announced an Extraordinary General Meeting for Nov. 14 to replace its independent board members. The weight-loss drugmaker has found itself in an increasingly chaotic situation
Novo Nordisk Says Mikael Dolsten Won't Seek Election to Board at Friday's Meeting
03:30am, Friday, 14'th Nov 2025
The drugmaker is holding a special shareholder meeting to vote on the appointment of a new board after the pharma giant lost its lead in the obesity-drug market.
Pfizer's ex-R&D chief Dolsten withdraws from Novo Nordisk board race
06:19pm, Thursday, 13'th Nov 2025
Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing personal reasons, the Danish drugmaker said on Thursday.
Novo: The Double Bottom Is In
05:44pm, Thursday, 13'th Nov 2025
Novo Nordisk remains a compelling long-term healthcare compounder, despite mixed Q3 results and recent stock weakness. NVO's growth is driven by global obesity drug demand, robust pipeline development
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
05:38pm, Thursday, 13'th Nov 2025
Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November
Novo Nordisk: Long-Term Brand Dominance At A Bargain
02:32pm, Thursday, 13'th Nov 2025
Dominant mega-caps with low debt deserve investors' attention. In times of prosperity, waste is common—and often sets the stage for strong cash generation when the cycle turns. Novo is enacted solid
Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
02:04pm, Thursday, 13'th Nov 2025
Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company
'Not been pretty': Novo Nordisk faces rare shareholder rebuke over board shake-up
10:33am, Thursday, 13'th Nov 2025
Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote against a board shake-up forced through by its dominant shareholder, the Novo No
Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs
07:15am, Thursday, 13'th Nov 2025
Telehealth company Mangoceuticals said on Thursday it has partnered with Eli Lilly and Novo Nordisk to sell the drugmakers' blockbuster weight-loss drugs through its platform.
Novo Nordisk: Reliable Weigh-Loss Growth Story With More Upside Than Bears Admit
10:05pm, Wednesday, 12'th Nov 2025
Novo Nordisk is significantly undervalued after a 20% stock price decline, now trading at a forward P/E of 13. NVO maintains strong growth prospects, driven by obesity treatment market expansion, inte
This biotech is halting its work with Novo Nordisk and laying off more people
05:59pm, Wednesday, 12'th Nov 2025
Korro is the latest to rethink its ties with the Danish pharma company.
Novo Nordisk CEO signals new appetite for risk in obesity deals
03:06pm, Wednesday, 12'th Nov 2025
When Novo Nordisk CEO Mike Doustdar learned in late September that Metsera had accepted a $7.3 billion rival bid from Pfizer , he was not ready to give up just yet on the company and its portfolio of
WeightWatchers to sell Novo Nordisk's Wegovy pill after 2026 launch
02:04pm, Wednesday, 12'th Nov 2025
WeightWatchers' CEO said on Wednesday it plans to sell Novo Nordisk's much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesit
